Related Experiment Video
Updated: Jul 18, 2026
Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice
Published on: January 2, 2013
Monocyte Locomotion Inhibitory Factor confers neuroprotection and prevents the development of murine cerebral malaria
A Galán-Salinas1, G Corral-Ruíz1, M J Pérez-Vega1
1Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, México City, Mexico; Posgrado en Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, México City, Mexico.
Abstract:
Cerebral malaria (CM) is a neurological complication derived from the Plasmodium falciparum infection in humans. The mechanisms involved in the disease progression are still not fully understood, but both the sequestration of infected red blood cells (iRBC) and leukocytes and an exacerbated host inflammatory immune response are significant factors. In this study, we investigated the effect of Monocyte Locomotion Inhibitory Factor (MLIF), an anti-inflammatory peptide, in a well-characterized murine model of CM. Our data showed that the administration of MLIF increased the survival and avoided the neurological signs of CM in Plasmodium berghei ANKA (PbA) infected C57BL/6 mice. MLIF administration down-regulated systemic inflammatory mediators such as IFN-γ, TNF-α, IL-6, CXCL2, and CCL2, as well as the in situ expression of TNF-α in the brain. In the same way, MLIF reduced the expression of CD31, CD36, CD54, and CD106 in the cerebral endothelium of infected animals and prevented the sequestration of iRBC and leucocytes in the brain microvasculature. Furthermore, MLIF inhibited the activation of astrocytes and microglia and preserved the integrity of the blood-brain barrier (BBB). In conclusion, our results demonstrated that the administration of MLIF increased survival and conferred neuroprotection by decreasing neuroinflammation in murine CM.
Insights
Monocyte Locomotion Inhibitory Factor (MLIF) administration improved survival and prevented neurological symptoms in a murine model of cerebral malaria (CM). MLIF reduced neuroinflammation and protected the blood-brain barrier, offering potential therapeutic benefits for CM.
Area of Science:
- Neuroscience
- Immunology
- Infectious Diseases
Background:
- Cerebral malaria (CM) is a severe neurological complication of Plasmodium falciparum infection.
- Disease mechanisms involve infected red blood cell sequestration, leukocyte infiltration, and exacerbated host immune responses.
- The role of anti-inflammatory agents in mitigating CM pathology requires further investigation.
Purpose of the Study:
- To evaluate the neuroprotective effects of Monocyte Locomotion Inhibitory Factor (MLIF) in a murine model of CM.
- To investigate MLIF's impact on inflammatory mediators, endothelial activation, and blood-brain barrier integrity in CM.
Main Methods:
- Utilized a well-characterized murine model of CM (Plasmodium berghei ANKA infected C57BL/6 mice).
- Administered MLIF and assessed survival rates, neurological signs, systemic and brain inflammatory markers (cytokines, chemokines).
- Analyzed expression of endothelial adhesion molecules (CD31, CD36, CD54, CD106), leukocyte and iRBC sequestration, and glial cell activation (astrocytes, microglia).
- Evaluated blood-brain barrier integrity.
Main Results:
- MLIF administration significantly increased survival and prevented neurological deficits in infected mice.
- MLIF down-regulated systemic inflammatory mediators (IFN-γ, TNF-α, IL-6, CXCL2, CCL2) and brain TNF-α expression.
- MLIF reduced cerebral endothelial expression of CD31, CD36, CD54, and CD106, inhibiting iRBC and leukocyte sequestration.
- MLIF inhibited astrocyte and microglia activation and preserved blood-brain barrier integrity.
Conclusions:
- MLIF demonstrates significant neuroprotective effects in a murine model of cerebral malaria.
- Administration of MLIF mitigates neuroinflammation by reducing inflammatory mediators, endothelial activation, and glial cell response.
- MLIF treatment enhances survival and preserves neurological function, highlighting its therapeutic potential for cerebral malaria.
More Related Videos
08:46Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
09:04In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
Published on: June 8, 2017
